Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - aciclovir, quantity: 25 mg/ml - injection, concentrated - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - aciclovir 25 mg/ml intravenous infusion is indicated for: ? non-immunocompromised patients: severe initial genital herpes, recurrent varicella zoster virus infection ? immunocompromised patients: herpes simplex infection, primary and recurrent varicella zoster infection, prophylaxis of herpes simplex infection ? herpes simplex encephalitis ? herpes simplex in neonates and infants up to 3 months of age

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - valaciclovir, quantity: 500 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; povidone; crospovidone; magnesium stearate; indigo carmine aluminium lake; titanium dioxide; hypromellose; polysorbate 80; macrogol 6000; macrogol 400 - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash. treatment of ophthalmic zoster. treatment of clinical episodes of genital herpes simplex infections. for the prevention of recurrent genital herpes in immunocompromised patients with creatinine clearance of > 15 ml/min. for the reduction of transmission of genital herpes in patients suffering from recurrent genital herpes. in addition to therapy with valaciclovir, it is recommended that patients use safer sex practices (see precautions). for prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - aciclovir, quantity: 25 mg/ml - injection, concentrated - excipient ingredients: sodium hydroxide; water for injections - treatment of severe initial genital herpes in the immunocompromised and non-immunocompromised. prophylaxis and treatment of herpes simplex infections in immunocompromised patients. treatment of shingles (varicella zoster virus) in immunocompetent patients in whom a serious course of the illness can be anticipated. treatment of initial and recurrent variacella zoster infections in immunocompromised patients. treatment of herpes encephalitis. treatment of herpes simplex infections in the neonate and infant up to 3 months of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - aciclovir, quantity: 25 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - aciclovir intravenous infusion is indicated for the purpose of:,1. promoting resolution of acute clinical manifestations of mucocutaneous herpes simplex virus infections in immunocompromised patients.,2. treatment of severe first episode primary or non-primary genital herpes in immune competent patients.,3. treatment of acute manifestations of varicella zoster virus infection in immunocompromised patients.,4. treatment of shingles (varicella zoster virus infection) in immune competent patients who show very severe acute local or systemic manifestations of the disease. benefits can be expected in patients with rash duration shorter than 72 hours. the use of the intravenous infusion may be warranted in only a small subgroup of immune competent patients with shingles.,5. treatment of herpes simplex encephalitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - aciclovir, quantity: 25 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - aciclovir intravenous infusion is indicated for the purpose of:,1. promoting resolution of acute clinical manifestations of mucocutaneous herpes simplex virus infections in immunocompromised patients.,2. treatment of severe first episode primary or non-primary genital herpes in immune competent patients.,3. treatment of acute manifestations of varicella zoster virus infection in immunocompromised patients.,4. treatment of shingles (varicella zoster virus infection) in immune competent patients who show very severe acute local or systemic manifestations of the disease. benefits can be expected in patients with rash duration shorter than 72 hours. the use of the intravenous infusion may be warranted in only a small subgroup of immune competent patients with shingles.,5. treatment of herpes simplex encephalitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - aciclovir, quantity: 25 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; sodium hydroxide; water for injections - aciclovir intravenous infusion is indicated for the purpose of:,1. promoting resolution of acute clinical manifestations of mucocutaneous herpes simplex virus infections in immunocompromised patients.,2. treatment of severe first episode primary or non-primary genital herpes in immune competent patients.,3. treatment of acute manifestations of varicella zoster virus infection in immunocompromised patients.,4. treatment of shingles (varicella zoster virus infection) in immune competent patients who show very severe acute local or systemic manifestations of the disease. benefits can be expected in patients with rash duration shorter than 72 hours. the use of the intravenous infusion may be warranted in only a small subgroup of immune competent patients with shingles.,5. treatment of herpes simplex encephalitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - aciclovir, quantity: 25 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; water for injections - aciclovir intravenous infusion is indicated for the purpose of 1. promoting resolution of acute clinical manifestations of mucocutaneous herpes simplex virus infections in immunocompromised patients. 2. treatment of severe first episode primary or non- primary genital herpes in immune competent patients. 3. treatment of acute manifestations of varicella zoster virus infection in immunocompromised patients. 4. treatment of shingles (varicella zoster virus infection) in immune competent patients who show very severe acute local or systemic manifestations of the disease. benefits can be expected in patients with rash duration shorter than 72 hours. the use of the intravenous infusion may be warranted in only a small subgroup of immune competent patients with shingles. 5. treatment of herpes simplex encephalitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - aciclovir, quantity: 25 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; water for injections - aciclovir intravenous infusion is indicated for the purpose of 1. promoting resolution of acute clinical manifestations of mucocutaneous herpes simplex virus infections in immunocompromised patients. 2. treatment of severe first episode primary or non- primary genital herpes in immune competent patients. 3. treatment of acute manifestations of varicella zoster virus infection in immunocompromised patients. 4. treatment of shingles (varicella zoster virus infection) in immune competent patients who show very severe acute local or systemic manifestations of the disease. benefits can be expected in patients with rash duration shorter than 72 hours. the use of the intravenous infusion may be warranted in only a small subgroup of immune competent patients with shingles. 5. treatment of herpes simplex encephalitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - aciclovir -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - aciclovir -